The endothelium modulates vascular tone by the observations are taken together, these states may be characterized by an attenuated release of NO, whereas release of vasodilator and vasoconstrictor substances, among them nitric oxide (NO) and endothelin (ET).
Introduction
initiating step in coronary atherosclerosis leading to In 1966 Lord Florey advanced the concept that the ischemic cardiomyopathy. endothelial cell served as a barrier to protect the vasFurchgott and Zawadski in 1980 provided the first cular wall, and was thus 'a cellophane wrapper of understanding of the humoral role of the endothe vascular tree'. 1 Today the endothelium has thelium. 3 These investigators reported that isolated emerged as a multi-functional endocrine organ arterial rings of aorta from rabbits precontracted which plays a fundamental role in cardiovascular with noradrenaline relaxed in response to acetylchoregulation. 1 Indeed, the endothelial cell synthesizes line. With removal of the endothelium, relaxations and releases biological active substances which play to acetylcholine were abolished. The authors cona role in the control of the underlying vascular cluded the existence of a diffusible vasoactive substsmooth muscle cell. These substances include ance termed endothelium derived relaxing factor potent vasodilating and growth inhibiting factors (EDRF). More recent studies have established that such as nitric oxide (NO), C-type natriuretic peptide EDRF is a short-lived and diffusible substance (CNP), prostacyclin and the newly discovered pepwhich activates soluble guanylate cyclase leading to tide, adrenomedullin. These factors function vasorelaxation. Activation of soluble guanylate through well characterized receptors and intracellucyclase and its second messenger cyclic GMP also lar signaling mechanisms which are associated with participates in the inhibition of vascular growth. enhanced intracellular production of cyclic guanoEvidence now supports the conclusion that EDRF is sine monophosphate (GMP) for NO and CNP, and NO, and that the enzyme responsible for NO procyclic adenosine monophosphate (AMP) for prostaduction by oxidation of guanidino nitrogen of argicyclin and adrenomedullin. In contrast, landmark nine has been identified as NO synthase which is studies have identified the peptide endothelin (ET) present in several mammalian tissues. which mediates potent vasoconstriction and is a coThe ability to inhibit NO production has led to an mitogen to promote proliferation of vascular smooth understanding of the physiological significance of muscle. ET also functions through well characthe NO system in vascular homeostasis. Inhibition terized receptor subtypes and through the increase of NO generation acutely results in systemic, renal in intracellular calcium. 2 The goal of this review and pulmonary vasoconstriction and long-term inhiwill be to define the important roles, particularly of bition results in hypertension and an impaired renal the NO system and ET in the pathophysiology of carability to increase sodium excretion in response to diovascular diseases, with a major emphasis upon high sodium intake, resulting in a form of volumedependent hypertension. 4 [15] [16] [17] [18] [19] In recent studies by Zeiher coronary arteries. In 1988 in the landmark study of et al, 12 the abnormality in coronary endothelial Yanigisawa and coworkers, the endotheliumfunction in humans with hypertension was derived vasoconstrictor, 21 amino acid peptide, ET localized primarily to the large echocardial coronary was discovered. 7 Endothelin is derived from a 203 arteries, with less impairment at the level of the coramino acid peptide precursor/preproendothelin onary microcirculation. These studies, however, which is cleaved after translation to form proendoinvolved only pharmacological challenges of the thelin in the presence of converting enzymes located coronary circulation with the endothelial-depenwithin vascular endothelial cells. After binding to dent vasodilator acetylcholine. Moreover, as human specific receptor subtypes, ET activates phosphosubjects with hypertension may also have associated lipase and diacylglycerol resulting in an increase in coronary artery disease and/or hypercholesteroleintracellular calcium which subsequently activates mia it is important to evaluate the effect of hypertenphosphorylation of myosin light chains and initiates sion upon the coronary endothelium in the setting vascular contraction.
of associated atherosclerosis and/or hypercholesterEndothelin is one of the most potent vasoconstricalemia, which may act synergistically to promote tor substances known and produces contraction in significant coronary endothelial dysfunction and both veins and arteries. Exogenous endothelin in possible myocardial ischemia. anesthetized animals in vitro results in profound
More recently, studies have provided a continuing systemic, coronary, pulmonary and renal vasoinsight into coronary endothelial dysfunction in constriction with activation of renin angiotensin humans with hypertension. In key studies by Frielaldosterone system. 8, 9 Endothelin also possess coingsdorf et al 20 the ability of large coronary epicardmitogenic properties in vitro resulting in stimulation ial vessels to dilate with exercise were evaluated in of DNA synthesis in cultured vascular smooth musnormal subjects and those with essential hypertencle cells which may be inhibited by ET-specific sion. These studies demonstrated that the challenge receptor antagonists. While ET functions as an of dynamic exercise, which may reflect the physioautocrine and paracrine factor, it is activated in carlogical behavior and responsiveness of the coronary diovascular disease states such as congestive heart circulation better than pharmacological interfailure, some forms of hypertension and atherosclerventions was assessed. These studies provided osis. 2, 10, 11 This activation in cardiovascular disease insight into significant alterations in coronary endostates underscores its pathophysiologic importance.
thelial function in patients with essential hypertension with and without significant coronary arterial
Coronary endothelial dysfunction in
stenosis. These studies reported that the change in cardiovascular diseases luminal area as assessed with quantitative angiography, markedly increased in normal subjects during As discussed above, the coronary endothelium plays exercise and in non-hypertensive patients with coran important role in modulating coronary vascular onary arterial disease there was no change in lumitone. Repeated studies have demonstrated an nal diameter in response to dynamic exercise. In impairment in endothelial function in large epicardcontrast, hypertensive subjects with normal coronial coronary vessels in a variety of experimental aniary arteries had no vasodilatory response to exermals, and in humans with atherosclerosis. 5, 12, 13 In cise. Most importantly, in the presence of coronary response to acetylcholine there is an absence of corartery stenosis there was a paradoxical vasoconstriconary vasodilatation or paradoxical coronary vasotion as demonstrated by a significant reduction in constriction which occurs in the setting of both early luminal diameter in response to exercise in hyperand late atherosclerosis. However, such an abnortensive patients. Indeed, these studies support the mality in epicardial coronary arteries may contribconcept that in the setting of essential hypertension ute little to the regulation of coronary blood flow there is coronary endothelial dysfunction, at least at and ischemia in the absence of coronary spasm as the level of a large epicardial vessels, which is myocardial perfusion is controlled by microvessels characterized by an impaired vasodilatory response less than 200 M in diameter. Nonetheless, if abnorto exercise. In a setting of coronary atherosclerosis, malities in large coronary vascular reactivity occurs at the site of coronary narrowing dynamic exercise together with abnormalities in the coronary results in paradoxical vasoconstriction. Further microcirculation, ischemia may occur. Indeed, in studies are required to better characterize myocaratherosclerosis and in hypertension, abnormalities dial perfusion and possible associated myocardial at the level of the microcirculation have been reported.
14 It is to speculate that coronary endoischemia in hypertensive subjects with and without coronary atherosclerosis to assess the significance of tration of acetylcholine with associated paradoxical coronary vasoconstriction. Furthermore, in response coronary microcirculation.
to intracoronary acetylcholine a further increase in coronary ET was observed in the group with coron-
Role of the NO system in coronary
ary endothelial dysfunction with no change in the endothelial dysfunction normal control group. These studies strongly support the concept for a role for ET as an early particiControversy exists with regard to alterations in the pant and a marker for coronary endothelial dysfunc-NO system, in coronary endothelial dysfunction, in tion in humans. While these studies provide an the setting of hypertension. In hypertension, as disimportant insight into the role of ET as a mediator cussed above, intracoronary acetylcholine adminisof coronary endothelial dysfunction, further studies tration may be associated with impaired coronary are required to characterize the role of ET in the vasodilatation. 12, 15 It has been speculated, based regulation of the coronary microcirculation in corupon studies on experimental models of hypertenonary endothelial dysfunction, not only in early sion, that there is an impairment in the NO system. atherosclerosis, but in other cardiovascular syn-A number of observations support this concept.
dromes such as hypertension. Studies have demonstrated that in the spontaneously hypertensive rat there is an increase in Therapeutic strategies for coronary NO synthase (NOS) which may result in enhanced NO production. However, these studies also suggest endothelial dysfunction an increased inactivation of NO, possibly secondary, As increasing evidence points to a role for coronary to the generation of superoxide radicals which may endothelial dysfunction as an initiating step in cordegrade NO. In addition, in models of salt-induced onary atherosclerosis leading to ischemic cardiomyhypertension, NOS may be impaired with reduced opathy, new therapeutic strategies have been synthesis and release of NO in a setting. Additional advanced to treat or prevent coronary endothelial studies suggest possibly impairment in cyclic GMP dysfunction and/or restore the endothelium to noraccumulation and vascular smooth muscle cells in mal responsiveness. Previous investigations have cardiovascular disease states such as coronary defined the effect of calcium channel antagonists atherosclerosis, by a mechanism which could upon the regulation of the coronary circulation in involve enhanced activity of cyclic GMP phosphodicoronary artery disease. Reports have demonstrated esterases resulting in enhanced degradation of the that such pharmacologic agents may prevent narsecond messenger, cyclic GMP.
rowing of stenotic coronary arteries and they induce vasodilatation in normal segments of the coronary arteries associated with atherosclerosis. Most
Endothelin in coronary endothelial
recently, Freilingsdorf et al 20 have defined the effect dysfunction of acute calcium channel antagonism upon coronary vasomotion of large coronary epicardial vessels in In early studies in which the effects of hypoxia were assessed on abnormal coronary endothelial function humans with essential hypertension. These studies were undertaken, as discussed above, employing in isolated vessels, the release of an endothelialderived vasoconstricting substance was postulated. 6 dynamic exercise as a physiological challenge. These investigators reported that patients with As discussed above, work by Yanagisawa and colleagues reported the existence of ET which was synhypertension had an impaired coronary vasodilatory response to dynamic exercise as defined an thesized and secreted by the endothelial cell. 7 In recent studies we have demonstrated that hyperchoimpaired increase in the luminal diameter of large epicardial vessels. In the setting of coronary stenosis lesteralemia induced by a 2% cholesterol diet in pigs elevates plasma ET concentration and enhances hypertensive subjects had a paradoxical vasoconstriction as defined by decrease in luminal diameter. coronary artery tissue ET. This extends previous studies from our laboratory which reported the actiThus, calcium antagonism prevented the abnormal response in normal and stenotic coronary arteries to vation of ET in plasma and aorta of humans with advanced atherosclerosis. 11 In our previous studies exercise in hypertensive patients and, thus, compensated for the endothelial dysfunction with reduced in hypercholesterol pigs, the endothelial-dependent vasodilator acetylcholine further increased plasma vasodilatory responses to exercise. The mechanism of this effect remains to be ET in hypercholesteralemia in association with coronary vasoconstriction. Thus, ET may play a sigcharacterized, however, several possibilities exist. One includes preventing abnormal vasoconstriction nificant role as a modulator of coronary vascular reactivity in the early stages of human atherosclerthrough a reduction in calcium influx into the vascular smooth muscle cell. Secondly, studies suggest osis and coronary endothelial dysfunction.
We recently extended these studies to the human that an increase in intracellular calcium, which could occur in response to calcium channel antagwith early atherosclerosis to better characterize a potential role of endogenous ET in participating in onism could result in the release of NO from the endothelial cell to mediate vasodilatation. 4 the coronary endothelial dysfunction which characterizes early coronary atherosclerosis. 21 These studAdditionally, calcium channel antagonism has been reported to reduce the generation of superoxide ies first demonstrated that both coronary and circulating ET were increased in patients who had an anions and, thus, may reduce the degradation of NO. Lastly, studies support a reduction in ET synthesis abnormal response to the intracoronary adminis-and release in response to acute and chronic calimportant endothelial-derived vasoconstricting factor. [23] [24] [25] cium channel antagonism. Further studies are While calcium antagonism and ACE inhibition required to characterize the action of calcium chanmay emerge as agents to restore or improve coronary nel antagonism upon coronary endothelial function endothelial dysfunction in the setting of cardioin cardiovascular disease states. vascular disease syndrome, it is possible that speIncreasing evidence suggests that endothelial dyscific antagonists to the ET receptor subtypes which function may be restored in response to angiotensinmediate coronary vasoconstriction may have efficonverting enzyme inhibition (ACE-I). The mechcacy. Most recently, we investigated the coronary anism of such a restoration of endothelial function vasoconstrictor response in vivo to ET administered may be multifactorial and include, first, the inhiat pathophysiologic concentrations. 26 We specifibition of ACE with a decrease in angiotensin II cally investigated the role of the ETA receptor sub-(ANG-II). The importance of inhibition of ANG-II is type to ET-mediated coronary vasoconstriction. underscored by the multiple vascular actions of this These studies demonstrated that the potent vasoconimportant cardiovascular peptide. Such actions stricting actions of ET in the coronary circulation include vasoconstriction, hypertrophy of vascular were completely abolished with an ETA-specific smooth muscle and cardiac myocyte, activation of receptor antagonist (FR139317). Such an action myocardial cardiac fibroblasts, activation of ET synoccurred not only at the level of the large epicardial thesis and increased secretion of aldosterone. In coronary vessels in which the reduction in coronary addition, ACE promotes the degradation of bradykiartery diameter was attenuated, but it also occurred nin. Thus, inhibition of ACE may lead to increased at the level of coronary microcirculation, as overall bradykinin which is known to be a coronary vasocoronary blood flow reductions to ET were aboldilation. The mechanism of coronary vasodilatation, ished with ETA receptor blockade. Thus, these studsecondary to bradykinin, involves both the release ies demonstrate that low concentrations of exogenof NO, as well as release of an endothelin-derived ous ET, which may mimic pathophysiologic hyperpolarizing factor, which may be CNP.
concentrations associated with cardiovascular disAdditionally, bradykinin through its own receptor ease states, results in coronary vasoconstriction has direct vasodilating properties. Thus, ACE-I mediated predominantly by the ETA receptor. If the emerges as a most unique pharmacologic agent ETA receptor remains expressed and responsive to which may be vascular protective and may restore endogenous ET in states of coronary cardiovascular endothelial dysfunction.
disease, a role of ETA receptor blockade may In a recent study by Mancini and coworkers in the emerge. However, further studies are required to TREND Study Trial ('Trial and Reversing Endocharacterize the role of endogenous ET in mediating thelial Dysfunction'), the investigators pursued an paradoxical coronary vasoconstriction and the syninvestigation of chronic ACE-I in attempting to drome of coronary endothelial dysfunction. understand the beneficial effects of this form of therapy in states such as hypertension, congestive heart failure and acute myocardial infarction. 22 They
Conclusion
tested the hypothesis that ACE-I with quinapril could improve coronary endothelial dysfunction in In conclusion, the endothelial cell emerges as an normotensive patients with coronary artery disease important endocrine gland which controls underlywithout heart failure, cardiomyopathy, or other ing coronary vascular smooth muscle cells reactivity major lipid abnormalities. In this double-blinded, and growth. While vasodilating and growth randomized, placebo-control study, the effects of inhibiting substances play a major role in preserving ACE-I on coronary artery diameter responses to acemyocardial profusion under normal physiological tylcholine were assessed with quantitative coronary conditions, an imbalance among these factors may angiography. Studies were performed at base-line occur in cardiovascular diseases. 27 Further studies and at 6 months follow-up. At 6 months only the are required to characterize the fundamental mechquinapril treated group, as compared to placebo, anisms which are responsible for these maladaptademonstrated significant net improvement in tions. Importantly, therapeutic strategies are emergresponse to incremental concentrations of acetylching, designed to restore normal coronary endothelial oline. Specifically, ACE-I significantly improved the function and these strategies include ACE inhicoronary vasodilating response to acetylcholine in bition, calcium antagonism, and possible endothelin patients with coronary artery disease. Thus, this receptor antagonism. It is hoped that early interstudy demonstrated that ACE inhibition improves vention with such pharmacologic agents could delay endothelial dysfunction in patients who are normota progression of coronary endothelial dysfunction to ensive and do not have severe hyperlipidemia or coronary atherosclerosis and, ultimately, to overt evidence of heart failure. Such beneficial effects of heart failure. Indeed, such a strategy is supported by ACE inhibition could be secondary, once again, to the landmark multi-center study SAVE, which demthe attenuation of the contractile effects of ANG-II onstrated that ACE inhibition initiated following or a reduction in superoxide generation by ACE with acute myocardial infarction in subjects with reduced enhanced NO production. Additionally, as reported ventricular function resulted in the reduction in by our group, ACE-I may also be a potent inhibitor ischemic events. 28 Thus, a strategy is emerging to of ET and, thus, these studies may, in part, be delay the progression of early coronary endothelial dysfunction to ischemic cardiomyopathy. explained by reduction in a generation of this
